Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 24.7688
- Book/Share 28.1903
- PB 4.7012
- Debt/Equity 0.2713
- CurrentRatio 1.7805
- ROIC 0.195
- MktCap 229472341068.0
- FreeCF/Share 3.8249
- PFCF 34.4708
- PE 16.4155
- Debt/Assets 0.1626
- DivYield 0.0176
- ROE 0.3184
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ABT | Jefferies | Hold | Buy | -- | $145 | July 18, 2025 |
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.
Read More
Abbott Laboratories shares gain on first quarter earnings beat
Published: April 16, 2025 by: Proactive Investors
Sentiment: Positive
Abbott Laboratories (NYSE:ABT) reported a profit beat for the first quarter driven by growth in its medical devices and diabetes care segments, as revenue fell short of estimates. The healthcare company beat earnings estimates by $0.02 with earnings per share (EPS) of $1.09 as revenue of $10.36 billion missed expectations of $10.41 billion.
Read More
Abbott (ABT) Q1 Earnings Beat Estimates
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $0.98 per share a year ago.
Read More
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Read More
5 Defensive Stocks to Buy for a Safe Portfolio Amid Tariff-Led Mayhem
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Five defensive stocks to buy at this soaring volatility are TAP, CNP, WEC, BSX, HCA.
Read More
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Global Expansion in EPD and Innovations Support Abbott Stock
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
ABT Stock to Gain From Early CE Mark Approval of Volt PFA System
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott achieves early CE Mark approval for the Volt PFA system.
Read More
New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve
Published: March 31, 2025 by: PRNewsWire
Sentiment: Neutral
TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years ABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years.
Read More
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer indication of contact between the Volt PFA catheter and targeted tissue ABBOTT PARK, Ill., March 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for …
Read More
Abbott Hosts Conference Call for First-Quarter Earnings
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Read More
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages Abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteries ABBOTT PARK, Ill., March 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary …
Read More
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Read More
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Published: March 04, 2025 by: Business Wire
Sentiment: Neutral
WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent.
Read More
My Best Dividend Aristocrats For March 2025
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
The latest trading day saw Abbott (ABT) settling at $133.17, representing a +0.79% change from its previous close.
Read More
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Read More
AHCO or ABT: Which Is the Better Value Stock Right Now?
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert B. Ford
- Employees 114000